dynamic-pdf

This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Log Out

Therapy Areas

Products

Order Vaccines

Order Samples

Order

Materials

Request Samples

Hospital Products

Vaccines

Patient Assistance

Pfizer Oncology Together

Pfizer RxPathways

Pfizer Dermatology Patient Access

Explore Content

Contact

Home

About

Dosing & Product Information

Dosing and
Product Information

Dosing and Storage

Ordering and Coding

Efficacy & Safety

Efficacy and
Safety

Clinical Data in Support of Biosimilarity

Safety Data in Support of Biosimilarity

Savings & Support

Savings and Support

Support and Resources

Co-Pay Assistance

Materials

Videos

Pfizer Commitment

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-NIV-USA-0383

You are now leaving Pfizer

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

INDICATIONS

Patients With Cancer Receiving Myelosuppressive Chemotherapy

NIVESTYM® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever

Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy

NIVESTYM® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML)

Patients With Cancer Undergoing Bone Marrow Transplantation

NIVESTYM® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg, febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by BMT

Patients Undergoing Autologous Peripheral Blood Progenitor Cell Collection and Therapy

NIVESTYM® is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis

Patients With Severe Chronic Neutropenia

NIVESTYM® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia

Please see full Prescribing Information, including Patient Information, and Instructions for Use, for NIVESTYM.